Dr Pachynski on the Ongoing Investigation of ARX517 in Advanced Solid Tumors
Russell Pachynski, MD, discusses the ongoing investigation of ARX517 in patients with advanced solid tumors in the phase 1/2 APEX-01 trial.
Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Russell Pachynski, MD, discusses the ongoing investigation of ARX517 in patients with advanced solid tumors in the phase 1/2 APEX-01 trial.
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (NASDAQ:XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living
SEATTLE, Sept. 28, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage biotechnology company focused on the development of novel antibody-drug conjugate
WALTHAM, Mass., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and...
WALTHAM, Mass., Sept. 27, 2023 -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with...